

Prof Dr. med. Bertram Glaß

Klinik für Hämatologie und Stammzelltransplantation
HELIOS Klinik Berlin-Buch
Schwanebecker Chaussee 50
D-13125 Berlin
Phone: +49 30 9041 100
Fax +49 30 9041 109
Mail: bertram.glass@helios-kliniken.de



Education and Certificates:

31.5.1989 Certification as physician-in-practice
21.3.1991 **Full certification as physician**
13.6.1991 **Academic degree „Medical Doctor“**
11.12.1996 **Board certification Internal Medicine (general)**
9.2.1999 **Habilitation (equivalent PhD)**
20.3.2002 **Board certification Hematology and Medical Oncology**
3.4.2002 Appointment as **Professor** and Vice director of the Department Hematology and Oncology at the University Hospital Göttingen

Positions and Employment:

Juni 1989 – January 1991 **Arzt im Praktikum (eqv. junior house officer, medical intern)** Departments of Immunology and Internal Medicine, University Hospital Kiel, Germany
1991 - 1997 **Assistensarzt (eqv. senior house officer, resident and fellow)**, Department of Internal Medicine (Hematology and Oncology), University Hospital Kiel, Germany
November 1999 – January 2001 **Oberarzt (eqv. consultant, attending physician)**, Department of Internal Medicine (Hematology and Oncology), University Hospital Kiel, Germany
January 2001 - September 2007 **Oberarzt (eqv. consultant, attending physician)**, Department of Internal Medicine (Hematology and Oncology), University Hospital Göttingen, Germany. Head of the stem cell transplant unit
October 2007-March 2017 **Head, Division of Stem Cell Transplantation**, at the Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg
August 2016- December 2017 **Director (comm.) Department Haematology, Oncology and Stem Cell Transplantation**, Asklepios Klinik St. Georg, Hamburg
Since April 2017 **Director, Clinic for Haematology and Stem Cell Transplantation**, HELIOS Klinik Berlin-Buch, Berlin

Engagement in clinical trials:

since 2005 Principal Investigator DSHNHL 2004-R4: „Offene, multizentrische, nicht-randomisierte Phase II Studie: Dosiseskulation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stamm-zelltransplantation zur Behandlung von refraktären und rezidierten aggressiven Non-Hodgkin-Lymphomen“ (EudraCT Nr.: 2004-003801-26)
since 2004 Principal Investigator DSHNHL 2004-R3: “Offene, multizentrische, randomisierte Phase II Studie: Allogene Stammzelltransplantation nach Vorbehandlung mit Fludarabin, Busulfan, Cyclophosphamid und GVHD-Prophylaxe mit oder ohne Rituximab bei Patienten mit Rezidiv eines aggressiven Non-Hodgkin-Lymphoms in besonderer Risikosituation im Alter von 18-65 Jahren
since 2010

Principal Investigator DSHNHL 2008-R6: "Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R2-DHAP)"

Since 2014 Principal Investigator DSHNHL 2008-R7: "Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R2-DHAP)"

Since 1997 Member of the steering committee of the "Deutschen Studiengruppe Hochmaligne Non-Hodgkin-Lymphome" (DSHNHL) (Board: Prof. M. Pfreundschuh, Homburg, Prof. Dr. L. Trümper, Göttingen, Prof. N. Schmitz, Kiel Prof. M. Löffler, Leipzig).

Since 2017 Member of the board of the German Lymphoma Alliance (GLA)

Since 2018 Speaker of the working party aggressive lymphoma within the GLA

Since 2020 Chairmen of the working party lymphoma within the EBMT